SCHEMBL3085046

SCHEMBL3085046

O=C(NS(=O)(=O)c1ccc2ccccc2c1)C(Cc1cnn(Cc2ccccc2)c1)C(=O)N1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.48
PLG P00747 5/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
F10 P00742 3/20 0.39
PLAU P00749 2/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
F2 P00734 3/20 0.39
MAPT P10636 1/20 0.39
LARS1 Q9P2J5 1/20 0.39
HTR7 P34969 1/20 0.39
F12 P00748 1/20 0.39
KLKB1 P03952 1/20 0.39
PROC P04070 1/20 0.39
HPN P05981 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3470358 0.87 LARS1 (0.46) KMT2AALDH1A1SMN1; SMN2F2LARS1
SCHEMBL27808919 0.84 MMP8 (0.44) MMP8KMT2A
SCHEMBL27808921 0.84 MMP8 (0.44) MMP8KMT2AF2
SCHEMBL3093093 0.81 MMP8 (0.43) MMP8PLGKMT2AMEN1PLAU
SCHEMBL3092893 0.81 MMP8 (0.53) MMP8PLGPOLBKMT2AMEN1
SCHEMBL3090643 0.81 LARS1 (0.43) PLGKMT2AF10ALDH1A1SMN1; SMN2
SCHEMBL3096410 0.79 MMP8 (0.51) MMP8PLGKMT2AMEN1ALDH1A1
SCHEMBL3090741 0.79 MMP8 (0.50) MMP8POLBKMT2AMEN1ALDH1A1
SCHEMBL3093166 0.79 LARS1 (0.41) PLGKMT2AMEN1F10PLAU
SCHEMBL3096206 0.79 LARS1 (0.41) PLGKMT2AMEN1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MMP8 3060/4885PLG 2448/4885POLB 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.